Brokerages Set Solid Biosciences Inc (NASDAQ:SLDB) Price Target at $5.88

Shares of Solid Biosciences Inc (NASDAQ:SLDB) have been given a consensus recommendation of “Hold” by the nine ratings firms that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating and six have given a hold rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $5.88.

Several brokerages have weighed in on SLDB. Zacks Investment Research lowered shares of Zai Lab from a “buy” rating to a “hold” rating in a report on Saturday, June 15th. Credit Suisse Group set a €19.00 ($22.09) price objective on shares of K&S and gave the stock a “neutral” rating in a report on Tuesday, May 14th. Chardan Capital set a $25.00 price target on shares of Tocagen and gave the company a “buy” rating in a report on Tuesday, May 14th. ValuEngine lowered shares of Woodward, Inc.Common Stock from a “buy” rating to a “hold” rating in a report on Tuesday, April 9th. Finally, Goldman Sachs Group lowered shares of E.ON SE Sponsored ADR (Germany) from a “buy” rating to a “neutral” rating in a report on Tuesday, May 14th.

In other news, Director Juan Andrey Zarur sold 8,000 shares of Solid Biosciences stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $10.00, for a total value of $80,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 31.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP grew its holdings in Solid Biosciences by 226.2% during the 1st quarter. Marshall Wace LLP now owns 69,813 shares of the company’s stock worth $642,000 after acquiring an additional 48,409 shares during the last quarter. NumerixS Investment Technologies Inc bought a new stake in Solid Biosciences during the 1st quarter worth about $184,000. Emory University grew its holdings in Solid Biosciences by 335.0% during the 1st quarter. Emory University now owns 298,887 shares of the company’s stock worth $2,750,000 after acquiring an additional 230,173 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Solid Biosciences during the 1st quarter worth about $325,000. Finally, Spark Investment Management LLC grew its holdings in Solid Biosciences by 78.7% during the 1st quarter. Spark Investment Management LLC now owns 318,100 shares of the company’s stock worth $2,926,000 after acquiring an additional 140,141 shares during the last quarter. 59.41% of the stock is owned by institutional investors and hedge funds.

SLDB stock traded up $0.07 during mid-day trading on Friday, hitting $5.31. 168,904 shares of the company were exchanged, compared to its average volume of 403,911. The firm has a market cap of $185.53 million, a P/E ratio of -2.36 and a beta of 2.08. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.99 and a quick ratio of 6.99. Solid Biosciences has a twelve month low of $4.46 and a twelve month high of $54.54. The stock’s fifty day moving average is $5.23.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.22). On average, equities research analysts expect that Solid Biosciences will post -3.09 EPS for the current year.

About Solid Biosciences

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

See Also: How the Consumer Price Index (CPI) is calculated?

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.